US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicus Pharma Ltd.

2.41

+0.03001.26%

Volume:140.78K

Turnover:334.96K

Market Cap:38.40M

PE:- -

High:2.50

Open:2.36

Low:2.31

Close:2.38

Loading ...

Overview Company News Filings

BRIEF-Medicus Pharma Ltd - Co And Helixnano Enter MoU For Vaccine Development - SEC Filing

Medicus Pharma and HelixNano Announce Vaccine Collaboration

Medicus Pharma Ltd - Co and Helixnano Enter Mou for Vaccine Development - SEC Filing

THOMSON REUTERS

Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology

Medicus Pharma Ltd. Files Initial Statement of Beneficial Ownership for Director Cathy McMorris Rodgers

Medicus Pharma Ltd. Appoints Deloitte as Lead Adviser for Doxorubicin Microneedle Array Licensing Deal

Medicus Pharma Ltd. Appoints Congresswoman Cathy McMorris Rodgers and Ajay Raju to Board of Directors

Medicus Pharma Ltd. Expands Clinical Trials and Announces Strategic Acquisition

Medicus Pharma Ltd. Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd

Medicus Pharma Ltd. Engages in Share Transactions: Issues 490,000 Shares to Yorkville and Sells 1,340,000 Warrants with New Inducement Agreement

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays

Medicus Pharma Ltd. Files Initial Beneficial Ownership Statement for Andrew Alasdair Smith, Chief Operating Officer

Medicus Pharma Ltd: Strategic Growth through Acquisition and Innovation Fuels Buy Rating

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. to Acquire Antev Ltd., Offering 17% Equity Stake and Up to $65 Million in Contingent Payments

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Ltd. Appoints Andrew Smith as Chief Operating Officer Amidst Clinical Development Expansion

Medicus Pharma Ltd. Secures $5 Million Debenture Agreement with Yorkville

Medicus Pharma Ltd. Announces Binding Letter of Intent to Acquire UK Biotech Firm Antev Ltd

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":2.41,"timestamp":1754424000000,"preClose":2.38,"halted":0,"volume":140779,"delay":0,"floatShares":6964800,"shares":15933444,"eps":0,"marketStatus":"Pre-Mkt","change":0.03,"latestTime":"08-06 06:46:52 EDT","open":2.36,"high":2.5,"low":2.3054,"amount":334956.8402563,"amplitude":0.081765,"askPrice":2.7,"askSize":1169,"bidPrice":2.2,"bidSize":80,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1754487000000},"marketStatusCode":1,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":2.41,"postHourTrading":{"tag":"盘后","latestPrice":2.31,"preClose":2.41,"latestTime":"19:43 EDT","volume":545,"amount":1306.61,"timestamp":1754437384269},"volumeRatio":0.49808380307792643},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":6964800,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.49808380307792643,"shares":15933444,"dividePrice":0,"high":2.5,"amplitude":0.081765,"preClose":2.38,"low":2.3054,"week52Low":1.8,"pbRate":"--","week52High":8.94,"institutionHeld":0,"latestPrice":2.41,"committee":-0.871898,"eps":0,"divideRate":0,"volume":140779,"delay":0,"ttmEps":0,"open":2.36,"prevYearClose":2.43,"prevWeekClose":2.57,"prevMonthClose":2.46,"prevQuarterClose":2.99,"fiveDayClose":2.59,"twentyDayClose":2.99,"sixtyDayClose":4.18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2556389049","title":"BRIEF-Medicus Pharma Ltd - Co And Helixnano Enter MoU For Vaccine Development - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2556389049","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556389049?lang=en_us&edition=fundamental","pubTime":"2025-08-04 20:13","pubTimestamp":1754309602,"startTime":"0","endTime":"0","summary":"BRIEF-Medicus Pharma Ltd - Co And Helixnano Enter MoU For Vaccine Development - SEC FilingAug 4  - Medicus Pharma Ltd MDCX.O:MEDICUS PHARMA LTD - CO AND HELIXNANO ENTER MOU FOR VACCINE DEVELOPMENT - SEC FILINGMEDICUS PHARMA LTD - CO AND HELIXNANO TO COLLABORATE ON MRNA VACCINE-LOADED MNAS PRODUCTION THROUGH JV - SEC FILINGFurther company coverage: MDCX.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nFWN3TW0Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2556389255","title":"Medicus Pharma and HelixNano Announce Vaccine Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2556389255","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556389255?lang=en_us&edition=fundamental","pubTime":"2025-08-04 19:59","pubTimestamp":1754308794,"startTime":"0","endTime":"0","summary":"An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. On August 4, 2025, Medicus Pharma Ltd. and Helix Nanotechnologies Inc. announ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-and-helixnano-announce-vaccine-collaboration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-and-helixnano-announce-vaccine-collaboration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2556386945","title":"Medicus Pharma Ltd - Co and Helixnano Enter Mou for Vaccine Development - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2556386945","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556386945?lang=en_us&edition=fundamental","pubTime":"2025-08-04 19:37","pubTimestamp":1754307458,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nFWN3TW0Q3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2556981386","title":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2556981386","media":"Reuters","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556981386?lang=en_us&edition=fundamental","pubTime":"2025-08-04 19:31","pubTimestamp":1754307065,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. Announces New Clinical Study for Thermostable mRNA Vaccine Utilizing Innovative Microneedle Array Technology. Medicus Pharma Ltd. has announced a new clinical study, in collaboration with Helix Nanotechnologies Inc., to explore the efficacy and safety of a thermostable mRNA-based vaccine using a proprietary Microneedle array  delivery platform. The study will compare the safety and preliminary efficacy of intramuscular injection versus intradermal MNA delivery of HelixNano's vaccine candidate, HN-0001, as part of a Phase 1 clinical bridging study. The study aims to assess the innovative combination of HelixNano's mRNA vaccine platform with Medicus' MNA technology. Results from this clinical study are anticipated to be presented in the future, contingent upon the successful formation of a joint venture between the two companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL34xW2N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2555831196","title":"Medicus Pharma Ltd. Files Initial Statement of Beneficial Ownership for Director Cathy McMorris Rodgers","url":"https://stock-news.laohu8.com/highlight/detail?id=2555831196","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555831196?lang=en_us&edition=fundamental","pubTime":"2025-07-31 22:36","pubTimestamp":1753972609,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has filed an initial statement of beneficial ownership. The filing names Cathy McMorris Rodgers as the beneficial owner in the role of Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDL8j7myx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2555048404","title":"Medicus Pharma Ltd. Appoints Deloitte as Lead Adviser for Doxorubicin Microneedle Array Licensing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2555048404","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555048404?lang=en_us&edition=fundamental","pubTime":"2025-07-30 18:57","pubTimestamp":1753873054,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has entered into a new engagement with Deloitte LLP, appointing the firm as the exclusive lead financial adviser. The collaboration aims to identify one or more partners for an out-licensing transaction involving Doxorubicin Microneedle Array , a treatment for Basal Cell Carcinoma in adults. This agreement allows for flexibility in the transaction structure, which may include licensing or other mechanisms. Medicus Pharma Ltd. will compensate Deloitte with a retainer and a contingent success fee upon the successful completion of a transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Ana","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL6brvM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2553221776","title":"Medicus Pharma Ltd. Appoints Congresswoman Cathy McMorris Rodgers and Ajay Raju to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2553221776","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553221776?lang=en_us&edition=fundamental","pubTime":"2025-07-23 19:31","pubTimestamp":1753270295,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced new additions to its board of directors following the company's annual and special meeting of shareholders. Congresswoman Cathy McMorris Rodgers and Ajay Raju, Esq., have been elected as new members. The meeting, held on July 22, 2025, in Toronto, Ontario, resulted in all eight nominees for the board being elected.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on July 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDLbKXzpC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2553474191","title":"Medicus Pharma Ltd. Expands Clinical Trials and Announces Strategic Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2553474191","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553474191?lang=en_us&edition=fundamental","pubTime":"2025-07-21 20:32","pubTimestamp":1753101162,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd ( ($MDCX) ) has provided an update. Medicus Pharma Ltd. announced its participation in the BTIG Virtual Biotech Conference 2025,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-ltd-expands-clinical-trials-and-announces-strategic-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-ltd-expands-clinical-trials-and-announces-strategic-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2553479621","title":"Medicus Pharma Ltd. Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2553479621","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553479621?lang=en_us&edition=fundamental","pubTime":"2025-07-21 19:31","pubTimestamp":1753097473,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced an expansion of its Phase 2 clinical study for SKNJCT-003, which began randomizing patients in August 2024 across nine clinical sites in the United States. Following a positively trending interim analysis in March 2025, showing over 60% clinical clearance, the investigational review board has increased the number of study participants to 90 subjects. The interim results are preliminary and may not necessarily reflect the final study outcomes. Additionally, the company is expanding its clinical trial sites into Europe. The lead asset, SkinJect Inc., focuses on a novel treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array. Furthermore, Medicus Pharma Ltd. will present at the BTIG Virtual Biotech Conference 2025, where Dr. Raza Bokhari, Executive Chairman and CEO, will participate in a fireside chat on July 30, 2025. The chat will be livestreamed for registered investors, and a recording will be avail","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL4Q7Fwv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2551090189","title":"Medicus Pharma Ltd. Engages in Share Transactions: Issues 490,000 Shares to Yorkville and Sells 1,340,000 Warrants with New Inducement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2551090189","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551090189?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:59","pubTimestamp":1752497966,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. Engages in Share Transactions: Issues 490,000 Shares to Yorkville and Sells 1,340,000 Warrants with New Inducement Agreement. Medicus Pharma Ltd. recently engaged in share transactions with YA II PN, Ltd.  under a Standby Equity Purchase Agreement . On July 9 and July 14, 2025, the company sold a total of 490,000 common shares to Yorkville. The shares were sold at approximately $3.2841 and $3.0216 per share, amounting to total proceeds of approximately $1,521,000. Additionally, the company entered into an inducement agreement with an accredited holder to exercise existing warrants for up to 1,340,000 shares, generating gross proceeds of approximately $3.75 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL38zQpf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2550663026","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2550663026","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550663026?lang=en_us&edition=fundamental","pubTime":"2025-07-09 21:05","pubTimestamp":1752066300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 09:05 ET (13:05 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2549627541","title":"Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays","url":"https://stock-news.laohu8.com/highlight/detail?id=2549627541","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549627541?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:31","pubTimestamp":1751974291,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment with Dissolvable Doxorubicin Microneedle Arrays. Medicus Pharma Ltd. has announced the submission of a Type C meeting request to the U.S. Food and Drug Administration  as part of its efforts to fast-track the clinical development program for treating Basal Cell Carcinoma  of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays . The meeting, anticipated for the week of October 6th, 2025, aims to discuss the D-MNA product development and secure the FDA's consent to accelerate the clinical pathway. The company is seeking the FDA's feedback on various aspects, including the selected doses for future studies and the appropriateness of the primary endpoint for upcoming trials. This development is a significant step in Medicus Pharma's ongoing regulatory review process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strive","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL3zr5Md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2548179338","title":"Medicus Pharma Ltd. Files Initial Beneficial Ownership Statement for Andrew Alasdair Smith, Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2548179338","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548179338?lang=en_us&edition=fundamental","pubTime":"2025-07-04 06:37","pubTimestamp":1751582278,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing mentions Andrew Alasdair Smith as the beneficial owner, who serves as the Chief Operating Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDLLZpl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2548459384","title":"Medicus Pharma Ltd: Strategic Growth through Acquisition and Innovation Fuels Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2548459384","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548459384?lang=en_us&edition=fundamental","pubTime":"2025-07-04 02:15","pubTimestamp":1751566513,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group mainta...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltd-strategic-growth-through-acquisition-and-innovation-fuels-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltd-strategic-growth-through-acquisition-and-innovation-fuels-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX"],"gpt_icon":0},{"id":"2548883311","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2548883311","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548883311?lang=en_us&edition=fundamental","pubTime":"2025-07-01 23:34","pubTimestamp":1751384040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 01, 2025 11:34 ET (15:34 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2547950650","title":"Medicus Pharma Ltd. to Acquire Antev Ltd., Offering 17% Equity Stake and Up to $65 Million in Contingent Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2547950650","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547950650?lang=en_us&edition=fundamental","pubTime":"2025-06-30 19:31","pubTimestamp":1751283064,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced a definitive agreement to acquire Antev Ltd., a UK-based clinical-stage drug development company. Under the terms of the agreement, Medicus will acquire all issued and outstanding shares of Antev in exchange for approximately 17% of Medicus's common shares. Antev shareholders are also eligible to receive up to $65 million in additional contingent payments, dependent on future FDA Phase 2 and New Drug Application approvals. The transaction is anticipated to close by the end of August 2025, pending the fulfillment of closing conditions, including Antev shareholder approval. Antev is currently focused on developing Teverelix, a GnRH antagonist, for treating cardiovascular high-risk prostate cancer and acute urinary retention.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL56P3p8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2545557417","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2545557417","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545557417?lang=en_us&edition=fundamental","pubTime":"2025-06-23 21:29","pubTimestamp":1750685340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2025 09:29 ET (13:29 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2545416251","title":"Medicus Pharma Ltd. Appoints Andrew Smith as Chief Operating Officer Amidst Clinical Development Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2545416251","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545416251?lang=en_us&edition=fundamental","pubTime":"2025-06-23 19:31","pubTimestamp":1750678290,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the appointment of Andrew Smith as Chief Operating Officer. Andrew brings over three decades of experience in asset management and financial operations, having previously served as Chief Executive of SR Asset Management and Co-Head of Americas at Aberdeen Asset Management Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on June 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL5Zy9Fj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABDN.UK","MDCX"],"gpt_icon":0},{"id":"2545170752","title":"Medicus Pharma Ltd. Secures $5 Million Debenture Agreement with Yorkville","url":"https://stock-news.laohu8.com/highlight/detail?id=2545170752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545170752?lang=en_us&edition=fundamental","pubTime":"2025-06-21 04:21","pubTimestamp":1750450874,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd., an Ontario-based company, has announced the entry into a significant securities purchase agreement with YA II PN, Ltd. . Under this agreement, Medicus Pharma will issue debentures totaling up to $5 million, with Yorkville having already purchased debentures worth $5 million in aggregate principal. The company has received net proceeds of $4.5 million from these transactions. The debentures, which mature on February 2, 2026, carry an annual interest rate of 8%, potentially increasing to 18% in case of specific defaults. The debentures are backed by a global guaranty agreement involving the company's subsidiaries.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDLb7KtvT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2542151667","title":"Medicus Pharma Ltd. Announces Binding Letter of Intent to Acquire UK Biotech Firm Antev Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2542151667","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542151667?lang=en_us&edition=fundamental","pubTime":"2025-06-12 19:31","pubTimestamp":1749727878,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the signing of a binding letter of intent to acquire Antev Ltd., a UK-based late clinical stage biotech company. Antev is developing Teverelix, a next-generation GnRH antagonist aimed at providing a first-in-market treatment for cardiovascular high-risk advanced prostate cancer patients and those experiencing first acute urinary retention relapse episodes due to an enlarged prostate. This acquisition marks a significant step for Medicus Pharma in expanding its portfolio and strengthening its position in the biotech industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on June 12, 2025, and is solely res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL6bRCRk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744689600000}}}